 Enhanced expression of paxillin has been detected in premalignant areas of hyperplasia, squamous metaplasia and goblet cell metaplasia, as well as dysplastic lesions and carcinoma in high-risk patients with lung adenocarcinoma.Mutations in "PXN" have been associated with enhanced tumor growth, cell proliferation, and invasion in lung cancer tissues.During tumor transformation, a consistent finding is that paxillin protein is recruited and phosphorylated.